## OUTCOME FORM



			-							
PLEASE COMPLETE	AT DE	ATH,	DISCHAR	GE OR DAY	28 WHICHEVER CO	OMES	FIRST			
1. HOSPITAL NAM	IE, ID	Т								
2. PATIENT RAND	OMIS	ΑΤΙΟ		ER						
<b>3. OUTCOME</b> <b>3.1 DEATH IN HOSPITA</b>	L				3.2 PATIENT ALIV	E (Select o	ne and provide c	date)		
a) Date of death (24hr)			<b>leath</b> (24hr)	a) Still in this hospital now (28 days after randomisation) – Date						
DAY (DD) MONTH (MM)	YEAR	(1111)	HOUR (HH)	MIN (MM)	DAY (DD)	n	иоптн (мм)		YEAR (YYYY)	
c) Primary Cause of death (ti	ck one opti	on)			b) Transferred to anot	her hosp	<b>ital –</b> Date o	f discharge		
Respiratory failure incl. A	RDS				DAY (DD)		иоптн (мм)		YEAR (YYYY)	
Congestive cardiac failure			c) Discharged home – Date of discharge							
Myocardial Infarction										
Sepsis			DAY (DD)	MONTH (MM) YEAR (YYYY)						
🗌 Multi organ failure					<b>3.3</b> Ability to self-care	at disch	arge versus b	pefore illne	ss (circle on	e):
Other, describe here (only one)			SAME AS BEFORE ILLN	ESS WORSE		ε	Better			
4. MANAGEMENT					6. COMPLICAT	IONS				
a) Admitted to ICU	YES	NO	Needed, no	ot available	a) Myocardial infarctio	n		YES	NO	
i) If yes, days in ICU (if none, write '0')					b) Congestive cardiac failure		YES	NO		
b) Ventilatory support	YES	NO	Needed, no	ıt available	c) Severe cardiac arrhythmia YES NO			NO		
i) Mechanical ventilation	YES	NO	Needed, no	ot available	d) Myocarditis YES NO			NO		

b) Ventilatory support	YES	NO	Needed, not available
i) Mechanical ventilation	YES	NO	Needed, not available
ii) CPAP/BIPAP	YES	NO	Needed, not available
c) Corticosteroids	YES	NO	
d) Antimalarial	YES	NO	
e) Antiviral	YES	NO	
f) Antibiotics	YES	NO	
g) Vasopressor/inotrope	YES	NO	

## **5. TRIAL TREATMENT GIVEN**

If standard care only, skip to Q6			Total number of days
a) Aspirin 150 mg	YES	NO	
b) Losartan 100 mg	YES	NO	
c) Losartan <100 mg	YES	NO	
d) Simvastatin 80 mg	YES	NO	

## 7. PERSON COMPLETING FORM

e) Respiratory failure including ARDS

f) Viral pneumonitis

g) Acute renal failure

j) Gastrointestinal bleeding

h) Sepsis

i) Stroke

a) Name	first/last name					
b) Job title						
c) Signature						
d) Date	DAY (DD)	моптн (мм)	YEAR (YYYY)			

YES

YES

YES

YES

YES

YES

NO

NO

NO

NO

NO

NO

## OUTCOME FORM



	OUTCOME CRF COMPLETION GUIDANCE			
Q no.	To avoid infection transmission from the use of paper, outcome data can be entered <b>directly</b> into the trial database at <u>https://ctu-</u> redcap.lshtm.ac.uk/. Please ensure that <u>all</u> outcome data is contained in the patient's medical records.			
OUT	COME			
3.1	• Do not enter multiple causes of death, please use clinical judgement to determine <u>one</u> primary cause.			
MAN	IAGEMENT			
4	<ul> <li>Only report management that occurred/was given <u>after</u> randomisation.</li> </ul>			
4.ai	<ul> <li>Include any days/ part days spent in High Dependency Unit. Part days count as '1'.</li> </ul>			
TRIA	L TREATMENTS GIVEN			
5	<ul> <li>If the patient received aspirin or simvastatin, only record the number of days the full dose was given.</li> <li>If the patient did not receive the allocated treatment or the full dose was not given, use the database notes to explain why.</li> </ul>			
CON	<b>IPLICATIONS</b> - Before answering 'YES', please ensure that the complication fulfils the definition given below:			
6	<ul> <li>If the patient experienced a complication not listed, and it is suspected to be related to the trial drug, please consider if it should be reported as a Serious Adverse Reaction.</li> </ul>			
6.a	<ul> <li>Myocardial infarction: Detection of rise and/or fall of cardiac biomarker values (preferably troponin) with at least one value above the 99th percentile of the upper reference limit <u>and with at least one of the following</u>:</li> <li>Symptoms of ischaemia</li> <li>ECG abnormalities: new or presumably new significant ST-T changes or new left bundle branch block or pathological Q waves</li> <li>Imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality</li> <li>Identification of an intracoronary thrombus by angiography or autopsy</li> <li>Cardiac death with symptoms suggestive of myocardial ischaemia</li> <li>Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile URL</li> </ul>			
6.b	<ul> <li>Congestive cardiac failure: A clinical diagnosis of heart failure may include the following symptoms: unusual breathlessness on light exertion, recurrent breathlessness when lying flat, fluid retention, jugular venous distension, pulmonary oedema on physical exam or chest x-ray presumed due to cardiac dysfunction.</li> </ul>			
6.c	Severe cardiac arrhythmia: Any arrhythmia that causes symptoms.			
6.d	Myocarditis: Established using histological, immunological or immunohistochemical criteria.			
6.e	<ul> <li>Respiratory failure incl. ARDS: Arterial oxygen tension (PaO<sub>2</sub>) of &lt;8.0 kPa (60 mmHg) and or an arterial carbon dioxide tension (PaCO<sub>2</sub>) of &gt;6.0 kPa (45 mmHg).</li> </ul>			
6.f	• Viral pneumonitis: Abnormal Chest X ray or CT findings consistent with COVID-19 infection.			
6.g	<ul> <li>Acute renal failure: 1) Increase in serum creatinine ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours; or</li> <li>2) Increase in serum creatinine ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or</li> <li>3) Urine volume &lt;0.5 mL/kg/h for 6 hours.</li> </ul>			
6.h	<ul> <li>Sepsis: The diagnosis of sepsis is based on the presence of both:</li> <li>1) Infection and 2) A systemic inflammatory response syndrome (SIRS). SIRS requires two or more of the following:</li> <li>Temperature &lt;36 °C or &gt;38 °C</li> <li>Respiratory rate &gt;20 breaths/min</li> <li>Heart rate &gt;90 beats/min</li> <li>White blood cell count &lt;4x10<sup>9</sup>/L (&lt;4000/mm<sup>3</sup>) or &gt;12x10<sup>9</sup>/L (&gt;12,000/mm<sup>3</sup>)</li> </ul>			
6.i	• Stroke: Defined as 'a new focal neurological deficit with signs and symptoms lasting more than 24 hours'.			
6.j	<ul> <li>Gastrointestinal bleeding: Any significant upper or lower GI bleeding. The diagnosis of significant bleeding is clinical but may include patients with hypotension, tachycardia, or those likely to need transfusion, urgent endoscopy or surgery.</li> </ul>			
PERS	SON COMPLETING THE FORM			
7.a	Please use the first and last name that is used on the trial team members log.			
7.c	<ul> <li>Signature of the person completing the paper form if applicable – this is confirmation that the data is accurate and, valid and that all outcome data is contained in the patient's medical records</li> </ul>			
IF a paper form is used, please ensure you:				
• Wh • Inse • Ind	ite clearly and legibly throughout, using CAPITAL LETTERS and using permanent black or blue ink pen. here multiple choices are given, circle the correct answer. ert dates using the format <b>DD/MM/YYYY</b> e.g. if 23 February 2018, record as 23/02/2018. icate all times using 24-hour clock in format of <b>hours:minutes</b> e.g. if 2:45 pm, record as 14:45. he time is midnight, record this as 00:00 the following day e.g. midnight on 23/02/2018 is 24/02/2018 at 00:00. Upload the data to the database within 24 hours of completion.			